本文選題：新藥品　切入點(diǎn)：價(jià)值評(píng)估　出處：《云南財(cái)經(jīng)大學(xué)》2014年碩士論文　論文類型：學(xué)位論文

【摘要】：改革開放以來(lái)，我國(guó)醫(yī)藥產(chǎn)業(yè)得到了快速發(fā)展，，支撐醫(yī)藥產(chǎn)業(yè)發(fā)展的是新藥品的研發(fā)，新藥品研發(fā)成為了醫(yī)藥企業(yè)在市場(chǎng)上獲取競(jìng)爭(zhēng)地位的主要途徑之一。我國(guó)新藥技術(shù)轉(zhuǎn)讓每年的交易金額近百億，新藥品價(jià)值評(píng)估研究具有重大的理論及現(xiàn)實(shí)意義。 由于新藥品的研發(fā)具有高投入、高技術(shù)、高風(fēng)險(xiǎn)、周期長(zhǎng)和過(guò)程復(fù)雜等特點(diǎn)，使形成的新藥品價(jià)值具有高成本和高附加值，二者對(duì)新藥品價(jià)值起著決定性作用。本文將新藥品研發(fā)周期劃分為三個(gè)階段，運(yùn)用馬克思主義經(jīng)濟(jì)學(xué)、資產(chǎn)評(píng)估學(xué)、等多種理論和方法，對(duì)每個(gè)階段新藥品價(jià)值的形成、影響因素和評(píng)估方法進(jìn)行了深入系統(tǒng)的分析和研究。指出新藥品價(jià)值包含基本價(jià)值、技術(shù)價(jià)值、使用價(jià)值和經(jīng)濟(jì)價(jià)值；指出影響新藥品價(jià)值的因素主要包括新藥品的研發(fā)成本、功能、技術(shù)有效期、技術(shù)水平、醫(yī)藥政策法規(guī)和市場(chǎng)因素，介紹了它們?nèi)绾螌?duì)新藥品價(jià)值產(chǎn)生影響；比較各評(píng)估方法后，指出了處于不同階段的新藥品價(jià)值的評(píng)估應(yīng)采用不同的評(píng)估方法；針對(duì)新藥品價(jià)值評(píng)估，對(duì)廣泛使用的收益法模型進(jìn)行調(diào)整，對(duì)模型中各參數(shù)的確定進(jìn)行詳細(xì)了分析。另外，本文還加入案例分析，對(duì)某新藥品價(jià)值的評(píng)估進(jìn)行了評(píng)估，旨在以實(shí)例說(shuō)明新藥品價(jià)值評(píng)估的過(guò)程、計(jì)算的關(guān)鍵因素、評(píng)估中應(yīng)注意的事項(xiàng)。 本文分為七個(gè)部分，系統(tǒng)的梳理了新藥品價(jià)值評(píng)估過(guò)程中影響因素，調(diào)整了傳統(tǒng)的收益法模型，通過(guò)參數(shù)量化影響因素的作用，使估值模型更適應(yīng)新藥品價(jià)值的評(píng)估。文中案例分析體現(xiàn)了理論分析對(duì)實(shí)際運(yùn)用的指引，使調(diào)整后的模型更具有實(shí)踐意義。 總的來(lái)說(shuō)，本文系統(tǒng)地論述了新藥品價(jià)值評(píng)估研究的主要理論和觀點(diǎn)，為新藥品價(jià)值評(píng)估問(wèn)題研究做出有益的探索。
[Abstract]:Since the reform and opening up, the pharmaceutical industry in China has developed rapidly. The development of new drugs is supported by the development of the pharmaceutical industry. New drug research and development has become one of the main ways for pharmaceutical enterprises to gain competitive position in the market. The annual transaction amount of new drug technology transfer in China is nearly 10 billion, so the research of new drug value evaluation has great theoretical and practical significance. Because of the characteristics of high investment, high technology, high risk, long period and complicated process, the new drugs have high cost and high added value. This paper divides the research and development cycle of new drugs into three stages, and applies various theories and methods, such as Marxist economics, asset appraisal, etc, to the formation of new drug value in each stage. The influence factors and evaluation methods are analyzed and studied deeply and systematically. It is pointed out that the value of new drugs includes basic value, technical value, use value and economic value, and that the factors influencing the value of new drugs mainly include the cost of research and development of new drugs. Function, technical validity period, technical level, medical policy, regulations and market factors, how they have an impact on the value of new drugs. This paper points out that different methods should be used to evaluate the value of new drugs at different stages, adjusts the widely used income method model, and analyzes in detail the determination of the parameters in the model. This paper also introduces a case study to evaluate the value of a new drug. The purpose of this paper is to illustrate the process of value evaluation of new drugs, the key factors of calculation, and the matters needing attention in the evaluation. This paper is divided into seven parts, systematically combing the influence factors in the process of new drug value evaluation, adjusting the traditional income model, and quantifying the effect of the factors through the parameters. The case analysis in this paper reflects the guidance of the theoretical analysis to the practical application and makes the adjusted model have more practical significance. In general, this paper systematically discusses the main theories and viewpoints of new drug value evaluation, and makes a useful exploration for the study of new drug value evaluation.
【學(xué)位授予單位】：云南財(cái)經(jīng)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：F426.72;F233

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 馬向陽(yáng),崔崢嶸,趙建科;企業(yè)單項(xiàng)無(wú)形資產(chǎn)的收益法評(píng)估[J];地質(zhì)技術(shù)經(jīng)濟(jì)管理;2003年01期

2 顧潤(rùn)豐;;延長(zhǎng)專利藥品保護(hù)期的策略簡(jiǎn)析[J];中國(guó)發(fā)明與專利;2011年10期

3 封春菲;;中國(guó)藥品市場(chǎng)的需求實(shí)證分析[J];河北科技大學(xué)學(xué)報(bào);2007年01期

4 陸瑜;陳振飛;;藥品的社會(huì)特性及其使用價(jià)值和價(jià)值[J];解放軍藥學(xué)學(xué)報(bào);2006年02期

5 駱正清,陳艷輝;無(wú)形資產(chǎn)評(píng)估的新方法探析[J];經(jīng)濟(jì)師;2001年12期

6 趙莉;邱家學(xué);;新藥研發(fā)項(xiàng)目的功能價(jià)值評(píng)價(jià)[J];價(jià)值工程;2010年02期

7 張坤;;無(wú)形資產(chǎn)評(píng)估的新方法-復(fù)合成本法[J];科技進(jìn)步與對(duì)策;2003年03期

8 平其能;;原創(chuàng)新藥的價(jià)值[J];臨床藥物治療雜志;2007年02期

9 張時(shí)開;胡元佳;尹恒;王一濤;;藥物靶點(diǎn)與經(jīng)濟(jì)價(jià)值——基于2000～2009年美國(guó)上市新藥的實(shí)證研究[J];科技管理研究;2011年23期

10 黃鎮(zhèn),錢雯,袁琳,施z

本文編號(hào)：1592284